Evidence mapPaperPMID 42365479Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Material-Encoded Synchronization of Immunogenic Cell Death With Adenosine A2A Receptor Blockade Reprograms the Tumor Microenvironment.

Xiangting Yi, Hanlou Yang, Junting Huang, Pengfei Wu, Shiying Zhou, Zunde Liao, Min Han, Zishan Chen, Xiaoyu Huang, Nan Ma and 3 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiangting YiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Hanlou YangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Junting HuangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Pengfei WuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Shiying ZhouState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Zunde LiaoState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Min HanState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Zishan ChenState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Xiaoyu HuangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Nan MaState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.
Jie ZhouDepartment of Breast Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, P. R. China.
Mingqiang LiLaboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, P. R. China.ORCID https://orcid.org/0000-0002-5178-4138
Yiling ZhongState Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou, Guangdong, P. R. China.ORCID https://orcid.org/0000-0001-5846-8018

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515220001National Natural Science Foundation of China 22377036National Natural Science Foundation of China 32501248Science and Technology Project of Guangzhou 2024A03J0649Young Top-notch Talent of the Guangdong Special Support Program 2024TQ08A112
6 · The paper itself

Abstract

Adenosine rapidly suppresses antitumor immunity through the adenosine A2A receptor (A2AR). Immunogenic cell death (ICD) releases extracellular ATP, which can be rapidly converted into immunosuppressive adenosine. We therefore designed BSCS@PHY to synchronize ICD induction with local A2AR blockade in the same spatiotemporal window, aiming to protect antigen priming from adenosine-mediated suppression. BSCS@PHY integrates a bismuth-copper diselenide core for photothermal heating, glutathione depletion, and chemodynamic hydroxyl-radical generation; hyaluronic-acid-modified phase-change materials for on-site activation; the A2AR antagonist SCH442416 for local A2AR blockade; and yeast cell wall (YCW) components for innate adjuvanticity. Thermography-guided irradiation confines activation within a controlled window, melts the phase-change shell to expose the catalytic surface, and coordinates ICD amplification with co-localized A2AR blockade and dendritic-cell activation. In 4T1 tumors, BSCS@PHY enables image-guided activation, enhances ICD hallmarks, lowers adenosine signaling, promotes dendritic-cell maturation and T-cell priming, and improves tumor control, with additional benefit when combined with anti-PD-L1. Loss-of-function comparisons support nonredundant contributions of A2AR blockade and YCW-mediated adjuvanticity. This material-encoded strategy aligns danger-signal generation with local A2AR blockade in the same tumor niche and offers a framework for pairing ICD induction with metabolic-checkpoint control in cold tumors.

Indexed as

adenosineadenosine 2A receptorimmunogenic cell deathnanosystemtumor microenvironment reprogramming

Identifiers

PMID42365479
PMCPMC13336662

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.